Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQ-2002 in R/R ALL or NHL
NCT06445803Phase 1Recruiting
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQ-2002 in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) (2 arms). Primary endpoints: Incidence of Dose-limiting toxicity at 28 days and Incidence and severity of adverse events at 15 years. Started May 2024; status: recruiting.
02
Drugs
KQ-2002
03
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06445803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445803.